|
Variables
|
n (%)
|
Train cohort n (%)
|
Validation cohort n (%)
|
P
|
|---|
|
Age
| |
879
|
377
| |
|
< 65
|
558 (44.4)
|
391 (44.5)
|
167 (44.3)
|
1.000
|
|
≥ 65
|
698 (55.6)
|
488 (55.5)
|
210 (55.7)
| |
|
Sex
|
|
Male
|
670 (53.3)
|
472 (53.7)
|
198 (52.5)
|
0.748
|
|
Female
|
586 (46.7)
|
407 (46.3)
|
179 (47.5)
|
|
Race
|
|
White
|
955 (76.0)
|
667 (75.9)
|
288 (76.4)
|
0.371
|
|
Black
|
210 (16.7)
|
153 (17.4)
|
57 (15.1)
|
|
Others
|
91 (7.2)
|
59 (6.7)
|
32 (8.5)
|
|
Grade
|
|
I (Well)
|
186 (14.8)
|
118 (13.4)
|
68 (18.0)
|
0.092
|
|
II (Moderately)
|
511 (40.7)
|
373 (42.4)
|
138 (36.6)
|
|
III (Poorly)
|
528 (42.0)
|
365 (41.5)
|
163 (43.2)
|
|
IV (Undifferentiated)
|
31 (2.5)
|
23 (2.6)
|
8 (2.1)
|
|
AJCC stage
|
|
III
|
239 (19.0)
|
166 (18.9)
|
73 (19.4)
|
0.905
|
|
IV
|
1017 (81.0)
|
713 (81.1)
|
304 (80.6)
|
|
T stage
|
|
T1
|
32 (2.5)
|
20 (2.3)
|
12 (3.2)
|
0.519
|
|
T2
|
332 (26.4)
|
227 (25.8)
|
105 (27.9)
|
|
T3
|
407 (32.4)
|
294 (33.4)
|
113 (30.0)
|
|
T4
|
485 (38.6)
|
338 (38.5)
|
147 (39.0)
|
|
N stage
|
|
N0
|
766 (61.0)
|
542 (61.7)
|
224 (59.4)
|
0.494
|
|
N1
|
490 (39.0)
|
337 (38.3)
|
153 (40.6)
|
|
M stage
|
|
M0
|
239 (19.0)
|
166 (18.9)
|
73 (19.4)
|
0.905
|
|
M1
|
1017 (81.0)
|
713 (81.1)
|
304 (80.6)
|
|
Surgery
|
|
No
|
938 (74.7)
|
645 (73.4)
|
293 (77.7)
|
0.121
|
|
Yes
|
318 (25.3)
|
234 (26.6)
|
84 (22.3)
|
|
Radiotherapy
|
|
No
|
1096 (87.3)
|
765 (87.0)
|
331 (87.8)
|
0.778
|
|
Yes
|
160 (12.7)
|
114 (13.0)
|
46 (12.2)
| |
|
Chemotherapy
|
|
No
|
438 (34.9)
|
304 (34.6)
|
134 (35.5)
|
0.793
|
|
Yes
|
818 (65.1)
|
575 (65.4)
|
243 (64.5)
| |
- AJCC American joint committee on cancer
